Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial
Cancer · 2025
DOI: 10.1002/cncr.35568 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2025. Verfasst von Renning Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Insulin Resistance, Dutasteride. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Purpose
Prior studies testing the association between insulin resistance (IR) and prostate cancer (PC) risk are inconsistent. We examined the association between Homeostatic Assessment of Insulin Resistance (HOMA‐IR; calculated from fasting baseline insulin and glucose) and PC in REDUCE, a 4‐year randomized trial of dutasteride vs. placebo for PC prevention. Experimental design All patients had prestudy negative biopsies and underwent study mandated biopsies at 2 and 4 years regardless of prostate‐specific antigen. Multivariable logistic regression models were used to investigate the associations between log‐transformed or categorized HOMA‐IR scores and PC risk. Multinominal regression was used to assess associations between HOMA‐IR scores and tumor grade (low grade [grade group 1]; high‐grade [grade groups 2–5]).
Results
Among 5430 REDUCE participants (1212 with PC; 856 low‐ and 356 high‐grade), higher HOMA‐IR was associated with lower PC risk (log‐HOMA‐IR: OR, 0.89; 95% CI, 0.80–0.99; p = .03; categorized HOMA‐IR: p ‐trend = .04). When stratified by grade, HOMA‐IR was significantly associated with reduced low‐grade PC risk (log‐HOMA‐IR: OR, 0.84; 95% CI , 0.74–0.94; p = .003; categorized HOMA‐IR: p ‐trend = .002) but was unrelated to high‐grade PC (log‐HOMA‐IR: OR, 1.02; 95% CI, 0.86–1.21; p = .81; categorized HOMA‐IR: p ‐trend = .26). Results were similar in placebo and treatment arms.
Conclusions
In summary, higher HOMA‐IR was associated with a reduced risk of low‐grade PC but was not associated with high‐grade disease. The mechanisms to explain these findings are unclear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tsinghua University, Beijing, China.
- Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Department of Urology, University of Louisville, Louisville, Kentucky, USA.
- The University of Illinois College of Medicine, Chicago, Illinois, USA.
- Durham VA Health Care System, Durham, North Carolina, USA.
- School of Medicine, University of California Irvine, Irvine, California, USA.
ORCID-Profile: Renning Zheng, Lourdes Guerrios-Rivera, Stephen J Freedland
Förderung
- NIH HHS
- NIDDK NIH HHS
- NCI NIH HHS
Zitieren
APA
Zheng, R., Daniels, J. P., Moreira, D. M., Eslamimehr, S., Freedland, A. R., Guerrios-Rivera, L., Fowke, J. H., & Freedland, S. J. (2025). Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. Cancer. https://doi.org/10.1002/cncr.35568
Vancouver
Zheng R, Daniels JP, Moreira DM, Eslamimehr S, Freedland AR, Guerrios-Rivera L, et al. Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. Cancer. 2025. doi:10.1002/cncr.35568
BibTeX
@article{Zheng2025,
author = {Zheng, Renning and Daniels, James P and Moreira, Daniel M and Eslamimehr, Shakiba and Freedland, Alexis R and Guerrios-Rivera, Lourdes and Fowke, Jay H and Freedland, Stephen J},
title = {Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35568}
}
EUVIMED